Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High - Should You Buy?

Key Points

• Halozyme shares reached a new 52-week high of $125.10, supported by strong momentum and a consensus analyst rating of “Moderate Buy.” However, the consensus price target of $99.55 is below the current share price.
• The company reported quarterly EPS of $2.28, exceeding expectations of $1.79, while revenue rose 47.7% year over year to $481 million. Management issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Insiders sold approximately $13.5 million worth of shares over the past three months, while institutional investors continue to hold a substantial 97.79% of the company’s outstanding stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) shares reached a new 52-week high on Wednesday. The stock traded as high as $125.10 and last traded at $124.37, with a volume of 2,149,026 shares changing hands. The stock had previously closed at $122.50.

Analyst Ratings Changes

HALO has been the topic of several research reports. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 13th. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Stifel Nicolaus set a $130.00 price target on Halozyme Therapeutics in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.55.

Halozyme Therapeutics Stock Performance

The firm has a market cap of $14.12 billion, a P/E ratio of 24.85, a P/E/G ratio of 0.46 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The business's 50-day simple moving average is $109.89 and its 200 day simple moving average is $85.91.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 over the last three months. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of HALO. CoreCap Advisors LLC boosted its position in Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 150 shares during the period. MidFirst Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $28,000. Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $30,000. Finally, Mather Group LLC. grew its stake in shares of Halozyme Therapeutics by 48.9% during the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.